RxDoctor Payments Data

Jonathan Miller, MD

Internal Medicine · Mobile, ALNPI 1619172285

Payments from drug & device makers

$10,233in general payments, 2019–2025

Across 767 payments — averaging $13.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Pfizer$785
  • GSK$739
  • Boehringer Ingelheim$588
  • Bayer$530
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$10,205100%
  • Education$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,233 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$213,118
Medicare patients
365
Services billed
5,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide186$211,643
MounjaroTirzepatide138$195,513
JardianceEmpagliflozin168$187,667
EliquisApixaban185$178,238
TrulicityDulaglutide58$77,266
RybelsusSemaglutide36$73,052
FarxigaDapagliflozin Propanediol45$53,706
XareltoRivaroxaban44$48,472
JanuviaSitagliptin Phosphate36$47,694
LinzessLinaclotide58$45,475
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog38$33,585
EntrestoSacubitril/Valsartan18$32,292
TrulancePlecanatide35$32,143
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$29,102
MyrbetriqMirabegron27$27,941

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,588$284,695222 claims
Lilly USA, LLCMounjaro, Trulicity$254$272,779196 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat$588$217,477225 claims
PfizerEliquis$785$178,238185 claims
MerckJanuvia, Janumet Xr, Dulera$89$76,15783 claims
AstraZenecaFarxiga, Symbicort$455$66,70882 claims
GSKTrelegy Ellipta, Breo Ellipta$739$54,20784 claims
Johnson & JohnsonXarelto$417$48,47244 claims
AbbVieLinzess$1,976$45,47558 claims
NovartisEntresto$350$32,29218 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$481$32,14335 claims
Astellas Pharma US IncMyrbetriq$95$27,94127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →